SPR Therapeutics LOGO 361 TM.jpg
Real-World Retrospective Review of Axial Neck Pain Relief Following Peripheral Nerve Stimulation of Cervical Medial Branch Nerves
21. September 2022 15:02 ET | SPR Therapeutics, Inc.
- Data presented at Pacific Spine Pain Society annual meeting - CLEVELAND, Sept. 21, 2022 (GLOBE NEWSWIRE) -- SPR Therapeutics shared data on the use of peripheral nerve stimulation (PNS) to...
ML2pt0_strengthimage_press_v1
Next Generation MicroLead 2.0 Now Available with the SPRINT® PNS System
06. September 2022 08:00 ET | SPR Therapeutics, Inc.
CLEVELAND, Sept. 06, 2022 (GLOBE NEWSWIRE) -- SPR Therapeutics announced today the formal introduction of its new MicroLead™ 2.0, designed to enhance the performance of the SPRINT® PNS System. As a...
SPR Therapeutics LOGO 361 TM.jpg
Peripheral Nerve Stimulation Pioneer Dr. Marc Huntoon Joins SPR Therapeutics as Director of Medical Affairs
02. August 2022 16:23 ET | SPR Therapeutics, Inc.
CLEVELAND, Aug. 02, 2022 (GLOBE NEWSWIRE) -- SPR Therapeutics is proud to announce the addition of Dr. Marc Huntoon to the company as Director of Medical Affairs. In this role, he will provide...
SPR Therapeutics LOGO 361 TM.jpg
SPR Therapeutics to Present Clinical Trial and Real-World Findings at ASPN 2022
14. Juli 2022 10:54 ET | SPR Therapeutics, Inc.
CLEVELAND, July 14, 2022 (GLOBE NEWSWIRE) -- SPR Therapeutics announced today that two presentations highlighting SPRINT® PNS in treating chronic pain will be featured at the American Society of...
SPR Therapeutics LOGO 361 TM.jpg
SPR Therapeutics Named a Top Workplace
26. Juni 2022 11:00 ET | SPR Therapeutics, Inc.
CLEVELAND, June 26, 2022 (GLOBE NEWSWIRE) -- SPR Therapeutics has been awarded a Top Workplaces 2022 honor by cleveland.com and The Plain Dealer. The award is based on employee feedback gathered...
SPR Therapeutics LOGO 361 TM.jpg
SPR Therapeutics Announces 10,000th SPRINT PNS Procedure for Patients Suffering from Life-altering Pain
12. Mai 2022 09:00 ET | SPR Therapeutics, Inc.
CLEVELAND, May 12, 2022 (GLOBE NEWSWIRE) -- Cleveland based medical device company SPR Therapeutics today announced a key milestone with the 10,000th patient treated using the SPRINT® PNS System....
SPR Therapeutics LOGO 361 TM.jpg
Real-world Study of SPRINT 60-day Peripheral Nerve Stimulation (PNS) Corroborates Published Clinical Study Results
06. Mai 2022 09:24 ET | SPR Therapeutics, Inc.
CLEVELAND, May 06, 2022 (GLOBE NEWSWIRE) -- SPR Therapeutics announced the publication of a study that evaluated the real-world impact of 60-day peripheral nerve stimulation (PNS) in the management...
SPR Therapeutics LOGO 361 TM.jpg
Prolonged Temporary Neurostimulation Treatment Period Offered by the SPRINT® PNS System May Optimize Pain Management Care Pathway While Reducing Healthcare Costs
15. März 2022 10:31 ET | SPR Therapeutics, Inc.
CLEVELAND, March 15, 2022 (GLOBE NEWSWIRE) -- SPR Therapeutics announced publication of a study in the Journal of Pain Research demonstrating how a longer initial treatment period may better...
SPR Therapeutics LOGO 361 TM.jpg
The PNS Trifecta: All Three SPRINT® PNS System Abstracts Submitted to ASRA 2021 Pain Medicine Meeting Receive President’s Choice Award
18. November 2021 12:32 ET | SPR Therapeutics, Inc.
CLEVELAND, Nov. 18, 2021 (GLOBE NEWSWIRE) -- SPR Therapeutics has been honored with three President’s Choice Abstract Awards at the 20th Annual ASRA Pain Medicine Meeting taking place November 18-20...
SPR Therapeutics LOGO 361 TM.jpg
FDA Clearance of an Expanded Indication for the SPRINT® PNS System Now Enables Treatment in Areas of the Head, Neck, and Torso
19. Oktober 2021 12:22 ET | SPR Therapeutics, Inc.
CLEVELAND, Ohio, Oct. 19, 2021 (GLOBE NEWSWIRE) -- SPR Therapeutics® has obtained clearance from the U.S. Food and Drug Administration (FDA) of a broader indication for use for its SPRINT Peripheral...